The National Institutes of Health says researchers have found a way to block a step in the HIV invasion process that may lead to the development of new drugs.
On July 12, 2017, the National Institutes of Health (NIH) announced that NIH researchers have blocked a step in the process HIV uses to inject its genetic material into cells. NIH researchers discovered the step in the HIV invasion process and used cultures of cells and tissues to find a way to chemically block the step and prevent HIV genetic material from entering cells.
The findings, published in Cell Host & Microbe, may lead to the development of new drugs to prevent HIV.
HIV infects a cell when a protein on the surface of HIV binds to the molecules on the cells surface. After biding, a sequence of events leads to HIV’s outer membrane fusing with the cell’s membrane. HIV genetic material then enters the cell. The researchers found that the binding process activates the TMEM 16F protein, which “transfers another molecule inside the cell membrane, phosphatidylserine, to the membrane’s outer surface.”
The researchers blocked the transfer of phosphatidylserine to the cell surface or attached another molecule to phosphatidylserine so it could not bind with HIV. This blocking prevented the virus from infecting the cell. NIH stated that “theoretically, developing drugs that could block each of these steps could provide the basis for treatments to prevent HIV from infecting cells, but much more research is needed.”
The NIH study was led by Leonid V. Chernomordik, PhD, at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Source: NIH
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.